Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 795 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06889805Recruiting
HDV screening for HIV and hepatitis B patients
This study tests whether people with both HIV and chronic hepatitis B should be checked for a third liver virus called HDV (hepatitis D). It helps find hidden infections so they can get the right care.
Hong KongAges 18 years+ - NCT07031063RecruitingPhase 4
HIV treatment study for people starting therapy
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Mexico City, AzcapotzalcoAges 18 years+ - NCT07059403RecruitingPhase 1
Safety and dose study of a new hepatitis B vaccine in healthy adults
This study is testing a new hepatitis B vaccine called SN2001 in healthy adults. It will check how safe the vaccine is, what dose works best, and how well it helps your body build protection against hepatitis B.
Herston, QueenslandAges 18–55 - NCT07122219Recruiting
Needle exchange access in federal prisons
This study looks at whether making needle and syringe programs easier to use helps more people in prison get clean needles. It's about reducing infection risks for everyone at the participating prisons.
Edmonton, AlbertaAges 18 years+ - NCT07199998Recruiting
How tampons and cups affect your vaginal health
This study looks at how tampons and menstrual cups affect your body's natural defenses and the healthy bacteria in your vagina. You might join if you are a healthy woman between 18 and 49 who has regular periods and uses or is willing to use these products.
Paris, Île-de-France RegionAges 18–49 - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT07342881RecruitingPhase 1
Single dose study of pevifoscorvir in people with kidney impairment
This study tests how a single dose of the study drug, pevifoscorvir, is processed in people with different levels of kidney function. It helps understand if the dose needs to be adjusted for people with kidney problems.
Orlando, FloridaAges 18–75 - NCT00187512Recruiting
Study of how HIV treatment changes outcomes over time
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
San Francisco, CaliforniaAges 18 years+ - NCT07442760Recruiting
Diary study for hepatitis D virus patients
This study uses a mobile diary app to track symptoms and quality of life for people living with hepatitis D infection. It may help researchers better understand the patient experience.
Bergamo, ItalyAges 18 years+ - NCT07530198RecruitingPhase 1
HIV DNA vaccine test for people on stable treatment
This study tests a new DNA vaccine (ICVAX) designed to help your immune system better control HIV. You'll receive injections over several months if your HIV is well-controlled with current medications.
Shatin, New TerritoriesAges 18–60 - NCT07589985Recruiting
Hepatitis B and Liver Health Study in Zambia
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
LusakaAges 18 years+ - NCT07668934Enrolling by invitationPhase 4
TAF for early and middle pregnancy with chronic hepatitis B
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
Guangzhou, GuangdongAges 20–40 - NCT07542951Enrolling by invitationPhase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Guangzhou, GuangdongAges 20–40 - NCT03159364RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests whether specially grown immune cells (T cells) can fight common viruses like CMV, EBV, or BK virus in people with weakened immune systems, such as after a stem cell or organ transplant. It may help when standard medicines don't work or can't be used.
Shenzhen, GuangdongAges 6 months–80 years - NCT05336851Recruiting
Emergency breathing test study for sudden lung infections
This trial tests an emergency breathing-related approach for adults with a sudden, community-acquired respiratory infection. It may help doctors quickly sort out what’s going on and guide early care.
Hong KongAges 18–100 - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+ - NCT07218211RecruitingPhase 4
Injectable PrEP study for Latine transgender women and gay men
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
Durham, North CarolinaAges 18 years+ - NCT07215871Enrolling by invitationPhase 1
Second H10N7 flu challenge for prior participants
This study tests whether people who have already been exposed to a lab-made H10N7 flu virus can be safely exposed again. It checks how their immune system responds and how long they shed the virus, in a controlled, isolated setting.
Bethesda, MarylandAges 18–55 - NCT04843852RecruitingPhase 1
Test vaccine added to hepatitis B treatment
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Baltimore, MarylandAges 18 years+ - NCT05390424Recruiting
Test dried blood spots for hepatitis and HIV
This study checks blood from a simple dried blood spot to screen for hepatitis B, hepatitis C, and HIV. It may help find infections early, which can allow earlier treatment.
AvranchesAges 18 years+ - NCT07694843RecruitingPhase 1
Study of ammoxetine for people with mild to moderate liver problems
This trial tests how the body processes ammoxetine in people with mild or moderate liver impairment compared to people with normal liver function. It aims to find out if the drug is safe and how it works in these groups.
Suzhou, JiangsuAges 18–75 - NCT07167251Recruiting
Low-dose steroids for immunotherapy-related liver inflammation
This trial tests whether using low-dose steroids can safely manage liver inflammation caused by immunotherapy. It may help patients who have moderate liver problems from their cancer treatment but haven't yet started high-dose steroids.
Basel, Canton of Basel-CityAges 18 years+
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 795 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.